FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Center For Cancer and Blood Disorders, Bethesda

Virginia Cancer Institute, Richmond

South Carolina Oncology Associates - SCRI, Columbia

Spartanburg Regional Medical Center, Spartanburg

Georgia Cancer Specialists - Northside, Atlanta

Florida Hospital Cancer Inst, Orlando

Florida Cancer Specialists; SCRI, Fort Myers

Tennessee Onc., PLLC - SCRI, Nashville

SCRI Tennessee Oncology Chattanooga, Chattanooga

Baptist Hospital East, Louisville

Toledo Comm. Onc. Program, Toledo

Oncology Hematology Care Inc, Cincinnati

Ingalls Cancer Research Center, Harvey

Ingalls Memorial Hospital; Cancer Research Center, Harvey

University of Chicago; Hematology/Oncology, Chicago

Saint Louis Cancer Care, LLP, Bridgeton

Research Medical Center - Antibiotic Research Associates, Inc., Kansas City

University of Oklahoma; Stephenson Oklahoma Canc Ctr, Oklahoma City

Ctr for Cancer and Blood Disorders, Fort Worth

South Texas Oncology & Hematology, P.A., San Antonio

Rocky Mountain Cancer Centers; Bone and Marrow Trans, Denver

Almac Clinical Technologies, San Francisco

Hem-Onc Assoc of Northern NJ, Morristown